ライフサイエンスコーパス: hemorrhagic

1 a stroke, of which 701 were ischemic and 107 hemorrhagic.

2 prevention is debated because of the risk of hemorrhagic adverse effects.

3 morrhage or hypotension; incidence of common hemorrhagic AEs (including pulmonary alveolar [11.8% and

4 related macular degeneration presenting with hemorrhagic and exudative changes within the macula and/

5 ng events requiring medical intervention, of hemorrhagic and nonhemorrhagic adverse events that occur

6 l sinus DAVFs were included and divided into hemorrhagic and nonhemorrhagic groups based on initial p

7 The CVR and CCS of the hemorrhagic and nonhemorrhagic groups were compared.

8 Cirrhosis is associated with hemorrhagic and thrombotic extrahepatic complications.

9 Hemorrhagic and thrombotic outcomes were retrieved </= 3

10 ), 128294 from stroke (16125 ischemic, 32591 hemorrhagic, and 79578 other), and 67914 from type 2 dia

11 ricted to UHCA, but also encompassed certain hemorrhagic cases in other HCA subtypes, particularly IH

12 thogens associated with diarrhea, dysentery, hemorrhagic colitis (HC) and hemolytic uremic syndrome (

13 al death and the development of ischemic and hemorrhagic complications and ICU-acquired infections.

14 ion of dabigatran to avoid the deaths due to hemorrhagic complications and thromboembolic stroke in c

15 (8.7%) patients exhibited severe ischemic or hemorrhagic complications during the ICU stay.

16 ation of vision, resolution of exudative and hemorrhagic complications with regression of polyps in p

17 patients with major bleeding or at risk for hemorrhagic complications, administration of platelet co

18 cessful reperfusion, good clinical outcomes, hemorrhagic complications, and mortality.

19 13%) patients but there was no PP-related or hemorrhagic complications.

20 of clotting factors, which may cause profuse hemorrhagic complications.

21 e bleeding that results from a wide range of hemorrhagic conditions.

22 Acute hemorrhagic conjunctivitis (AHC) is a painful, contagiou

23 The presence of adnexal hemorrhagic content was associated with nonviable ovarie

24 of BK viremia (range, 0-1.0 x 10 copies/mL), hemorrhagic cystitis (present/absent), and data on kidne

25 n (HCT), polyoma-BK virus is associated with hemorrhagic cystitis and also with polyomavirus nephropa

26 en of 14 patients treated for BKV-associated hemorrhagic cystitis experienced complete resolution of

27 Hemorrhagic cystitis is an inflammatory and ulcerative b

28 new therapeutic target for the treatment of hemorrhagic cystitis.

29 with BK viremia and was not associated with hemorrhagic cystitis.

30 Haufen was not significantly correlated with hemorrhagic cystitis.

31 nd evaluated them as potential predictors of hemorrhagic death (HD) in the first 30 days of treatment

32 e outcome of cardiovascular death (including hemorrhagic death), nonfatal myocardial infarction, or n

33 ignificant implications in both because many hemorrhagic deaths could be preventable, and TIC is asso

34 nding on the pervasiveness of the infection, hemorrhagic dengue fever or dengue shock syndrome.

35 Rabbit hemorrhagic disease (RHD) is a veterinary disease that a

36 Arenaviruses cause fatal hemorrhagic disease in humans.

37 any parts of the world, often causing severe hemorrhagic disease in livestock.

38 African swine fever is an acute hemorrhagic disease of pigs.

39 morrhagic fever (CCHF) is a tick-borne viral hemorrhagic disease seen exclusively in humans.

40 eering of chimeric VLPs, derived from rabbit hemorrhagic disease virus (RHDV) for presentation of for

41 In Portugal, rabbit hemorrhagic disease virus (RHDV) was reported in 1989 an

42 Yellow fever is an acute viral hemorrhagic disease which threatens approximately one bi

43 s a highly lethal pathogen, causing a severe hemorrhagic disease with a high fatality rate.

44 s are responsible for severe and often fatal hemorrhagic disease.

45 the arenavirus family, rapidly cause severe hemorrhagic diseases that can be fatal.

46 y known as Dengue Fever, infection can cause hemorrhagic disorders and death in humans and non-human

47 exhibited endothelial necrosis surrounded by hemorrhagic effusions and pulmonary edema.

48 0.91; P=0.005) but had no effect on risk for hemorrhagic events (HR, 1.00; 95% CI, 0.50-2.00; P=1.00)

49 Hemorrhagic events occurred in 6 patients on ASA 81 mg+d

50 in any language and reporting thrombotic or hemorrhagic events.

51 val, 1.2-9.5 versus ASA 81 mg; P = 0.02) for hemorrhagic events.

52 unin virus, the causative agent of Argentine hemorrhagic fever (AHF), is an arenavirus identified as

53 Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne viral hemorrhag

54 Crimean-Congo hemorrhagic fever (CCHF) is a widely distributed, viral,

55 ut, in severe cases, life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS)

56 se, and it can cause life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).

57 NNIg) is the greatest risk factor for dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).

58 V-1-4) that causes Dengue fever (DF), Dengue hemorrhagic Fever (DHF) or Dengue shock syndrome (DSS).

59 develop the life-threatening diseases dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).

60 enting as dengue fever (DF; mild) and dengue hemorrhagic fever (DHF; severe) and subjects with a nons

61 ) arenavirus and causative agent of Bolivian hemorrhagic fever (HF).

62 t of a severe human disease known as Marburg hemorrhagic fever (MHF).

63 e are 4 families of viruses that cause viral hemorrhagic fever (VHF), including Filoviridae.

64 to manage the threat of Lassa fever, a viral hemorrhagic fever (VHF).

65 uding 15 viruses (chikungunya, Crimean-Congo hemorrhagic fever [CCHF] virus, dengue, Ebola virus, Bun

66 The arenavirus Lassa causes severe hemorrhagic fever and a significant disease burden in We

67 k of severe dengue disease, including dengue hemorrhagic fever and dengue shock syndrome.

68 ffects livestock, RVFV can also cause lethal hemorrhagic fever and encephalitis in humans.

69 ses are zoonotic pathogens that cause severe hemorrhagic fever and pulmonary syndrome.

70 elop severe manifestations, including dengue hemorrhagic fever and shock syndrome, resulting in ~25,0

71 d undifferentiated fever to life-threatening hemorrhagic fever and shock.

72 The Epi Info Viral Hemorrhagic Fever application (Epi Info VHF) was develop

73 GP1 glycoprotein from Junin virus (JUNV), a hemorrhagic fever arenavirus endemic in central Argentin

74 Hemorrhagic fever arenaviruses (HFAs) cause high rates o

75 Hemorrhagic fever arenaviruses (HFAs) pose important pub

76 Hemorrhagic fever arenaviruses cause lethal infections i

77 Hemorrhagic fever arenaviruses pose significant threats

78 ed data from the Sierra Leone National Viral Hemorrhagic Fever Database, contact tracing records, Ken

79 r decades, the gold-standard immunoassay for hemorrhagic fever detection has been the enzyme-linked i

80 naviruses, chiefly Lassa virus (LASV), cause hemorrhagic fever disease in humans and pose serious pub

81 ssa fever virus, can cause severe and lethal hemorrhagic fever diseases with high mortality and morbi

82 Marburg virus (MARV) infection is a lethal hemorrhagic fever for which no licensed vaccines or ther

83 a highly pathogenic virus that causes severe hemorrhagic fever in humans and is responsible for epide

84 highly pathogenic viruses that cause severe hemorrhagic fever in humans and other mammals with high

85 (BDBV) is the etiological agent of a severe hemorrhagic fever in humans with a case-fatality rate ra

86 ses are zoonotic pathogens that cause severe hemorrhagic fever in humans.

87 contagious, severe and often lethal form of hemorrhagic fever in humans.

88 rging zoonotic virus that causes often-fatal hemorrhagic fever in infected humans for which preventat

89 hese receptors has the potential to decrease hemorrhagic fever in patients.

90 us is responsible for outbreaks of Argentine hemorrhagic fever in South America, where 5 million peop

91 irus that caused an outbreak of severe viral hemorrhagic fever in southern Africa.

92 able for clinical evaluation.IMPORTANCE EBOV hemorrhagic fever is one of the most lethal viral infect

93 Transmission of hemorrhagic fever New World arenaviruses from their rode

94 Ebola virus causes devastating hemorrhagic fever outbreaks for which no approved therap

95 r of the Filoviridae family and the cause of hemorrhagic fever outbreaks.

96 rus (MARV) has caused outbreaks of filoviral hemorrhagic fever since its discovery in 1967.

97 Ebola virus disease (EVD), a severe viral hemorrhagic fever syndrome caused by Ebola virus (EBOV)

98 data from non-human primate models of viral hemorrhagic fever to better understand the host transcri

99 Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne Nairovir

100 Like other viruses, Crimean-Congo hemorrhagic fever virus (CCHFV) is known to regulate apo

101 Of these serogroups, the Crimean-Congo hemorrhagic fever virus (CCHFV) serogroup comprises sole

102 Tick-borne Crimean-Congo hemorrhagic fever virus (CCHFV), a member of the family

103 One member is Crimean-Congo hemorrhagic fever virus (CCHFV), which is responsible fo

104 Treatment of blood samples from hemorrhagic fever virus (HFV)-infected patients with 0.1

105 infected crab-eating macaques, while simian hemorrhagic fever virus (SHFV) causes lethal viral hemor

106 then crab-eating macaques with either simian hemorrhagic fever virus (SHFV) or Kibale red colobus vir

107 eviously reported for the arterivirus Simian hemorrhagic fever virus (SHFV).

108 of vOTUs originating from the Crimean-Congo hemorrhagic fever virus, Erve virus, and Nairobi sheep d

109 esponding to the challenges of confronting 2 hemorrhagic fever viruses will require continued investm

110 Dengue hemorrhagic fever was defined according to 1997 World He

111 The incidence of dengue hemorrhagic fever was less than 0.3 episodes per 100 per

112 face.IMPORTANCE Although outbreaks of Korean hemorrhagic fever were first recognized during the Korea

113 Ebola virus causes hemorrhagic fever with a high case fatality rate for whi

114 a virus is the etiological agent of a severe hemorrhagic fever with a high mortality rate.

115 dent hosts but can lead to severe and lethal hemorrhagic fever with bleeding and multiorgan failure i

116 o includes Ebola virus (EBOV), causes lethal hemorrhagic fever with case fatality rates that have exc

117 pathogen that can cause severe outbreaks of hemorrhagic fever with high mortality rates.

118 Hantaviruses, Bunyaviridae, cause hemorrhagic fever with renal syndrome (HFRS) and hantavi

119 Hemorrhagic fever with renal syndrome (HFRS) was conside

120 anslation apparatus.IMPORTANCE Crimean-Congo hemorrhagic fever, a highly contagious viral disease end

121 the causative agent of dengue fever, dengue hemorrhagic fever, and dengue shock syndrome and is ende

122 rotect at-risk individuals against Argentine hemorrhagic fever, but it has not been licensed in the U

123 zed by "abortion storms" in ruminants and by hemorrhagic fever, encephalitis, and blindness in humans

124 by a high rate of abortion in ruminants and hemorrhagic fever, encephalitis, or blindness in humans.

125 veloped filamentous RNA virus causing severe hemorrhagic fever, enters cells by macropinocytosis and

126 es, infected individuals can also experience hemorrhagic fever, neurological disorders, liver failure

127 one of several viruses that can cause viral hemorrhagic fever, which is characterized by uncontrolle

128 ortant human pathogen responsible for dengue hemorrhagic fever, whose global incidence has increased

129 dae family and can cause outbreaks of severe hemorrhagic fever, with high mortality rates in humans.

130 he focus on vaccine development against this hemorrhagic fever-causing pathogen, and as a consequence

131 on mechanisms between arenaviruses and other hemorrhagic fever-causing viruses, such as Ebola, Marbur

132 n virus is used to protect against Argentine hemorrhagic fever.

133 mptoms, such as hepatitis, encephalitis, and hemorrhagic fever.

134 oviruses, are the causative agents of severe hemorrhagic fever.

135 ated with a cluster of human cases of severe hemorrhagic fever.

136 potential therapeutic agents to treat Lassa hemorrhagic fever.

137 each year, many of which develop into fatal hemorrhagic fever.

138 continent to cause epidemics of highly fatal hemorrhagic fever.

139 Filoviruses (Ebola and Marburg) cause severe hemorrhagic fever.

140 causative agents of dengue fever and dengue hemorrhagic fever.

141 hagic fever virus (SHFV) causes lethal viral hemorrhagic fever.

142 uses responsible for dengue fever and dengue hemorrhagic fever.

143 t Africa and responsible for severe cases of hemorrhagic fever.

144 Hemorrhagic fevers caused by viruses were identified in

145 es for managing patients infected with viral hemorrhagic fevers have evolved as new information has b

146 Arenaviruses can cause lethal hemorrhagic fevers in humans with few preventative and t

147 are responsible for severe life-threatening hemorrhagic fevers in western Africa and South America.

148 Viral hemorrhagic fevers, because of their high mortality rate

149 vaccines against Lassa and other arenaviral hemorrhagic fevers.

150 tly asymptomatic infections to severe, viral hemorrhagic fevers.

151 may be useful in the treatment of arenavirus hemorrhagic fevers.

152 t of effective therapies to treat arenaviral hemorrhagic fevers.

153 agnostic replacement for the ELISA for viral hemorrhagic fevers.

154 ic stroke and suspected pump thrombosis) and hemorrhagic (gastrointestinal bleeding and hemorrhagic s

155 y more restrictive (lower median CCS) in the hemorrhagic group than in the nonhemorrhagic group (1 vs

156 Twenty-six patients had hemorrhagic infarction and 15 had parenchymal hemorrhage

157 ated prolonged survival of rats subjected to hemorrhagic injury (HI) when treated with DCA.

158 re subjected ICH and neurologic deficits and hemorrhagic lesion outcomes were evaluated at 72 hours a

159 r beta-catenin in brain endothelial cells of hemorrhagic lesions of hemorrhagic stroke patients.

160 mptoms, 34% had neurologic symptoms, 43% had hemorrhagic manifestations, and 23% had signs of plasma

161 imates, including coagulation abnormalities, hemorrhagic manifestations, petechial rash, and a severe

162 wed a complex, 4.5-cm mass consistent with a hemorrhagic metastasis.

163 ed T-cell-independent and TNFalpha-dependent hemorrhagic necrosis at early times, followed by later C

164 We report a case of hemorrhagic occlusive retinal vasculitis (HORV) after pr

165 of presentation, diagnosis, and outcomes of hemorrhagic occlusive retinal vasculitis (HORV).

166 Hemorrhagic occlusive retinal vasculitis is a rare, pote

167 Considering the association of hemorrhagic occlusive retinal vasculitis with vancomycin

168 MR images in 84 patients with hemorrhagic or proteinaceous cysts and 50 patients with

169 Reader 2 scored morphology of 59 (70%) hemorrhagic or proteinaceous cysts as score 1 on MR imag

170 Reader 1 scored morphology of 68 (81%) hemorrhagic or proteinaceous cysts as score 1 on MR imag

171 R images can be used to differentiate benign hemorrhagic or proteinaceous cysts from RCC, although pr

172 Results SI ratio and attenuation of hemorrhagic or proteinaceous cysts were significantly hi

173 Acute Multifocal Hemorrhagic Retinal Vasculitis (AMHRV) is a rare disease

174 orted treatment options for Acute Multifocal Hemorrhagic Retinal Vasculitis are oral corticosteroids,

175 the first reported case of Acute Multifocal Hemorrhagic Retinal Vasculitis occurring in a child.

176 We report a child with Acute Multifocal Hemorrhagic Retinal Vasculitis who was treated with aggr

177 of the need to treat severe Acute Multifocal Hemorrhagic Retinal Vasculitis with aggressive immunosup

178 rl who developed unilateral Acute Multifocal Hemorrhagic Retinal Vasculitis, which later on progresse

179 Fundus examination revealed peripheral hemorrhagic retinal vasculitis.

180 ion was associated with ocular hypertension, hemorrhagic retinopathy, vitreous hemorrhage, combined t

181 e torpedo maculopathy, vascular changes, and hemorrhagic retinopathy.

182 d adverse events but a paradoxical increased hemorrhagic risk.

183 Viral hemorrhagic septicemia virus (VHSV) is a pathogenic fish

184 Hemorrhagic shock (HS) due to trauma remains a major cau

185 organ injury and dysfunction associated with hemorrhagic shock (HS) in the rat.

186 polysaccharide(LPS)-induced shock (LPSS) and hemorrhagic shock (HS).

187 After 4 hours of hemorrhagic shock (removal of 30% of the blood volume, s

188 cally instrumented pigs underwent 3 hours of hemorrhagic shock (removal of 30% of the calculated bloo

189 lled exosomes, secreted into ML after trauma/hemorrhagic shock (T/HS) have the potential to activate

190 onist) was studied using a pressure-targeted hemorrhagic shock and a volume-targeted hemorrhagic shoc

191 s show that alcohol intoxication exacerbated hemorrhagic shock and resuscitation-induced hypotension

192 nvestigated how alcohol intoxication impacts hemorrhagic shock and resuscitation-induced microvascula

193 cardiac output in an adult porcine model of hemorrhagic shock and resuscitation.

194 leakage following alcohol intoxication plus hemorrhagic shock and resuscitation.

195 re designed in a mouse model of resuscitated hemorrhagic shock and tissue trauma (HS/T).

196 erse effects of transfusion with SRBCs after hemorrhagic shock are ameliorated by treatment with eith

197 Patients with hemorrhagic shock at admission were excluded.

198 lso, 50% of massively transfused patients in hemorrhagic shock demonstrated SD physiology on admissio

199 impact of acute B2 receptor blockade during hemorrhagic shock in angiotensin-converting enzyme inhib

200 fects of hyperoxia during resuscitation from hemorrhagic shock in swine with preexisting coronary art

201 Hyperoxia during resuscitation from hemorrhagic shock in swine with preexisting coronary art

202 tate (DCA) on survival in an animal model of hemorrhagic shock in the absence of fluid resuscitation.

203 can be successfully used in the treatment of hemorrhagic shock in the absence of fluid resuscitation;

204 Ischemia-induced lethal cell swelling during hemorrhagic shock is a key mediator of resuscitation inj

205 Hemorrhagic shock is a leading cause of death in people

206 Fluid resuscitation following hemorrhagic shock is often problematic, with development

207 Hemorrhagic shock often progresses to multiple organ fai

208 Fifteen hemorrhagic shock patients requiring RBC transfusion.

209 ransfusion on sublingual microcirculation in hemorrhagic shock patients.

210 macrocirculation and the hemoglobin level in hemorrhagic shock patients.

211 Hemorrhagic shock was induced in rats by withdrawing 60%

212 thirty-five adult blunt trauma patients with hemorrhagic shock who survived beyond 48 hours after inj

213 otensin-converting enzyme inhibitors) before hemorrhagic shock, 4) shocked mice treated with angioten

214 During hemorrhagic shock, acute B2 receptor blockade significan

215 One hour after volume-targeted hemorrhagic shock, blood lactate was measured to evaluat

216 During resuscitation from near-lethal hemorrhagic shock, hyperoxia attenuated hyperinflammatio

217 During volume-targeted hemorrhagic shock, icatibant prevented blood pressure lo

218 following combined alcohol intoxication and hemorrhagic shock, in a dose-related manner.

219 of resuscitation with SRBCs after 2 hours of hemorrhagic shock, mice that received SRBCs were given a

220 r adverse reaction to liver transplantation, hemorrhagic shock, or resection.

221 Therefore, in patients with hemorrhagic shock, perfusion-sensitive organs such as th

222 During pressure-targeted hemorrhagic shock, the mean blood volume withdrawn was s

223 tely at the end of and 12 and 22 hours after hemorrhagic shock, we measured hemodynamics, blood gases

224 Hemorrhagic shock-induced tissue hypoxia induces hyperin

225 swine due to an increased susceptibility to hemorrhagic shock.

226 ls is a lifesaving therapy for patients with hemorrhagic shock.

227 iple organ failure and decrease mortality in hemorrhagic shock.

228 eted hemorrhagic shock and a volume-targeted hemorrhagic shock.

229 n in vivo models of endotoxemia, sepsis, and hemorrhagic shock.

230 creased histone acetylation in kidneys after hemorrhagic shock/resuscitation was restored by valproic

231 ven protective for myocardial infarction and hemorrhagic stroke ( approximately 2-4 drinks: relative

232 4; P=0.008) and a nonsignificant increase in hemorrhagic stroke (0.8% versus 0.6%; HR, 1.38; 95% CI,

233 rson-years; p < 0.001) and the incidences of hemorrhagic stroke (1.21 vs. 4.19 events per 1000 person

234 uses of death were multiorgan failure (26%), hemorrhagic stroke (24%), and progressive heart failure

235 h retinal vein occlusion had higher risks of hemorrhagic stroke (adjusted HR, 2.54 [95% CI, 1.50-4.30

236 hemic stroke (aHR = 2.03, P = .003), but not hemorrhagic stroke (aHR = 1.24, P = .696), than the cont

237 chemic stroke (HR, 1.27; 95% CI, 1.23-1.32), hemorrhagic stroke (HR, 1.36; 95% CI, 1.26-1.46), myocar

238 , ischemic stroke (HR, 1.27; 1.02-1.59), and hemorrhagic stroke (HR, 1.70; 1.01-2.84).

239 The clinical epidemiology of neonatal hemorrhagic stroke (NHS) remains undefined, hindering th

240 are most sensitive to the relative risk for hemorrhagic stroke and CVD mortality but are affected by

241 Using a rodent model of hemorrhagic stroke and next-generation proteomic and met

242 in children with SCA without screening), and hemorrhagic stroke in children and adults with SCA (3% a

243 diagnostic test to distinguish ischemic from hemorrhagic stroke in patients presenting with stroke-li

244 onstrated a higher risk of both ischemic and hemorrhagic stroke in subjects with COPD and revealed th

245 Neonatal hemorrhagic stroke is more common than previously report

246 is important to note that NAC did not worsen hemorrhagic stroke outcome, suggesting that it exerts th

247 endothelial cells of hemorrhagic lesions of hemorrhagic stroke patients.

248 GI bleeding and 0.32 (CI, -0.05 to 0.82) for hemorrhagic stroke per 1000 person-years of aspirin expo

249 myocardial infarction, ischemic stroke, and hemorrhagic stroke using DerSimonian and Laird random-ef

250 Power to detect effects on hemorrhagic stroke was limited.

251 The pooled relative risks of hemorrhagic stroke were 2.24 (95% CI, 1.19-4.21) in wome

252 age, 79.6 years; 31 377 women [58.9%]) with hemorrhagic stroke were identified in the study period.

253 ected associations were an increased risk of hemorrhagic stroke with lower sodium-to-potassium ratio

254 d hemorrhagic (gastrointestinal bleeding and hemorrhagic stroke) events occurring outside of the hosp

255 s of being transferred included younger age, hemorrhagic stroke, and higher stroke severity, but havi

256 l reductions in major bleeding, particularly hemorrhagic stroke, and mortality.

257 protective benefits on all-cause mortality, hemorrhagic stroke, and new-onset dialysis in HCV-infect

258 dial infarction (AMI), ischemic stroke (IS), hemorrhagic stroke, and new-onset dialysis were evaluate

259 e menopause and gestational hypertension for hemorrhagic stroke, and oophorectomy, HDP, preterm deliv

260 Ischemic stroke, hemorrhagic stroke, any stroke, and stroke mortality.

261 ding transient ischemic attack, ischemic and hemorrhagic stroke, cerebral venous thrombosis, and nons

262 Aside from hemorrhagic stroke, corresponding associations of cardio

263 However, differences in hemorrhagic stroke, disabling/fatal stroke, cardiovascul

264 epatobiliary, and neurocognitive events; and hemorrhagic stroke, heart failure, cancer, and noncardio

265 e, cerebrovascular disease, ischemic stroke, hemorrhagic stroke, hypertensive heart disease, cardiomy

266 kely to be older, smokers, have a history of hemorrhagic stroke, hypothyroidism, and dementia, and le

267 ption activity is a key pathogenic factor in hemorrhagic stroke, seizure activity, and central nervou

268 n the brain and are strongly associated with hemorrhagic stroke, seizures, and other neurological dis

269 odifiable risk factors for both ischemic and hemorrhagic stroke, while hypertension, smoking, diet, a

270 n of ischemic injury, and presumed perinatal hemorrhagic stroke.

271 th an increased risk of stroke, particularly hemorrhagic stroke.

272 ischemic stroke; and HR 1.53 (0.91-2.59) for hemorrhagic stroke.

273 increased fatal and nonfatal GI bleeding and hemorrhagic stroke.

274 ted with increased risk of stroke overall or hemorrhagic stroke.

275 associated factors, and outcomes of neonatal hemorrhagic stroke.

276 target molecule to limit brain damage during hemorrhagic stroke.

277 positive for ischemic stroke and inverse for hemorrhagic stroke.

278 hemic stroke), and 5 were presumed perinatal hemorrhagic stroke.

279 , seizures, focal neurological deficits, and hemorrhagic stroke.

280 receiving the device had significantly fewer hemorrhagic strokes (hazard ratio 0.22, P=0.004); (2) a

281 , the risks of gastrointestinal bleeding and hemorrhagic strokes associated with aspirin use outweigh

282 (IS), 15% transient ischemic attacks, and 9% hemorrhagic strokes.

283 that are associated with severe neuronal and hemorrhagic syndromes.

284 lation of TGF-beta/BMP signaling: hereditary hemorrhagic telangiectasia (HHT) and cerebral cavernous

285 Hereditary hemorrhagic telangiectasia (HHT) is a highly debilitatin

286 Hereditary hemorrhagic telangiectasia (HHT) is a potentially life-t

287 e kinase 1 (ALK1; ACVRL1), causes hereditary hemorrhagic telangiectasia (HHT).

288 nt and disabling manifestation of hereditary hemorrhagic telangiectasia (HHT).

289 quality of life in patients with hereditary hemorrhagic telangiectasia (HHT; also known as Osler-Web

290 PAVMs (including 403 [90.5%] with hereditary hemorrhagic telangiectasia) were recruited to a prospect

291 ership, 47 [79.7%]; P = .49) and symptomatic hemorrhagic transformation (drip and ship, 2 [2.0%]; mot

292 ography perfusion (CTP) imaging, can predict hemorrhagic transformation (HT) in patients with acute i

293 associated with increased risks of cerebral hemorrhagic transformation and angioedema.

294 use was evident in 19 of the 51 cases of non-hemorrhagic transformation NHS (37%).

295 mary and secondary intracerebral hemorrhage, hemorrhagic transformation of ischemic injury, and presu

296 hich 32 (67%) were idiopathic, 30 (35%) were hemorrhagic transformation of primary ischemic injuries

297 nths, mortality by 3 months, and symptomatic hemorrhagic transformation.

298 stributed between idiopathic, secondary, and hemorrhagic transformation.

299 p, overall and by type of event (ischemic or hemorrhagic), using survival analyses and Cox proportion

300 um antiviral drug that may be useful against hemorrhagic viruses.